COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00089206
Recruitment Status : Completed
First Posted : August 5, 2004
Last Update Posted : December 19, 2014
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia

Brief Summary:

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.

Condition or disease Intervention/treatment Phase
Intraocular Melanoma Melanoma (Skin) Biological: incomplete Freund's adjuvant Biological: multi-epitope melanoma peptide vaccine Biological: sargramostim Phase 2

Detailed Description:


  • Determine the antitumor immune response in patients with unresectable stage III or IV melanoma treated with vaccine comprising multiple synthetic melanoma peptides, sargramostim (GM-CSF), and Montanide ISA-51.

OUTLINE: Patients receive vaccine comprising multiple synthetic melanoma peptides, sargramostim (GM-CSF), and Montanide ISA-51 on days 1, 8, 15, 29, 36, and 43. Patients undergo removal of the lymph node draining the vaccination site on day 22 to assess immune response.

PROJECTED ACCRUAL: A maximum of 29 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma
Study Start Date : August 2002
Actual Primary Completion Date : November 2005

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of melanoma

    • Unresectable stage III or IV disease
    • Mucosal or ocular disease allowed
  • Positive HLA-A1, -A2, or -A3 expression



  • 12 and over

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • Absolute neutrophil count > 1,000/mm^3
  • Platelet count > 100,000/mm^3
  • Hemoglobin > 9 g/dL


  • Liver function tests ≤ 2.5 times upper limit of normal (ULN)


  • Creatinine ≤ 1.5 times ULN


  • No New York Heart Association class III or IV heart disease


  • Weight ≥ 100 pounds
  • Not pregnant or nursing
  • No other malignancy within the past 5 years except squamous cell or basal cell skin cancer without known metastasis, carcinoma in situ of the breast, or carcinoma in situ of the cervix


Biologic therapy

  • No prior vaccination with any of the peptides used in this protocol
  • More than 1 year since prior melanoma vaccine therapy
  • More than 4 weeks since prior immunotherapy
  • More than 4 weeks since prior growth factors
  • More than 4 weeks since prior allergy shots


  • More than 4 weeks since prior chemotherapy

Endocrine therapy

  • More than 4 weeks since prior steroid therapy


  • More than 4 weeks since prior radiotherapy


  • Prior tumor resection allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00089206

Layout table for location information
United States, Virginia
Cancer Center at the University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Craig L. Slingluff, MD University of Virginia
Layout table for additonal information
Responsible Party: Craig L Slingluff, Jr, Professor of Surgery, University of Virginia Identifier: NCT00089206    
Other Study ID Numbers: 10049
First Posted: August 5, 2004    Key Record Dates
Last Update Posted: December 19, 2014
Last Verified: December 2014
Keywords provided by Craig L Slingluff, Jr, University of Virginia:
stage III melanoma
stage IV melanoma
recurrent melanoma
recurrent intraocular melanoma
iris melanoma
extraocular extension melanoma
ciliary body and choroid melanoma, medium/large size
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Freund's Adjuvant
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic